SEC Tracker
Get the app

Dianthus Therapeutics DNTH

Simrat Randhawa (DNTH) Director John Doe purchased 10,000 shares of the company's stock for a total transaction value of $200,000 on Nov 14, 2025. This insider buying activity signals a bullish sentiment from a key company director, potentially indicating their confidence in Dianthus Therapeutics' future prospects.

Simrat Randhawa, insider filing for DNTH

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Dianthus Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Stoke Therapeutics STOK public float $592M, Jun 30, 2025
  2. Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
  3. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Evolus EOLS public float $560M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.